Biocon Limited
BIOCON · 532523 · Healthcare · Pharmaceuticals
- Market cap
- Rs 57,346 Cr
- P/E
- No data: the source has not published this figure.
- P/B
- 1.69x
- 52W high / low
- Rs 447.15 / Rs 318.4
Our computed operating_margin (8.11%) diverges from BSE's own published figure (20.11%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong. Our computed net_margin (2.40%) diverges from BSE's own published figure (8.36%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong.
About Biocon
Biocon Limited is listed on the NSE under the symbol BIOCON and on the BSE under scrip code 532523. It is classified in the Healthcare sector, industry: Pharmaceuticals. It is a constituent of BSE 200, NIFTY 200, NIFTY 500, NIFTY Midcap 150 and NIFTY Pharma. The company listed on 7 Apr 2004 and has a face value of Rs 5.
The latest available end-of-day price is Rs 351.9 (+0.34% on the day), for a market capitalisation of Rs 57,346 Cr. Price-to-book is 1.69x. The 52-week range is Rs 318.4 to Rs 447.15. The latest price is 26% of the way from the 52-week low to the 52-week high.
Against the 15-company comparison set from the official BSE basic industry Pharmaceuticals, its market capitalisation is 0.5 times the peer median of Rs 1,09,706 Cr. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For FY26 (year ended 31 Mar 2026), Biocon Limited reported revenue of Rs 16,927 Cr and net profit of Rs 369 Cr, with a net margin of 2.18% and earnings per share of Rs 2.82 (consolidated statements).
Year-on-year change: revenue +4.85%; net profit −74.20%; EPS −66.67%. Three-year compound annual growth rate: revenue +14.35%; net profit −16.91%.
At the same date the balance sheet shows total assets of Rs 63,651 Cr, shareholders' equity of Rs 34,032 Cr, total debt of Rs 14,825 Cr, cash of Rs 2,417 Cr, a debt-to-equity ratio of 0.44 and operating cash flow of Rs 1,994 Cr.
On a trailing-twelve-month basis the filings add up to revenue of Rs 17,321 Cr, net income of Rs 416 Cr and a net margin of 2.40%.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, Biocon Limited's ownership is split: promoters 44.68%; foreign institutional investors (FIIs) 8.64%; domestic institutional investors (DIIs) 29.30%; retail and other shareholders 17.20%.
Compared with the filing for 30 Jun 2026: promoter holding 0.00 percentage points; FII holding +0.50 percentage points; DII holding +5.92 percentage points.
The same filing lists reported promoter pledge of 0.00% and 3,93,051 shareholders on record.
Recent filings and corporate actions
200 BSE corporate announcements were filed by Biocon Limited in the past twelve months; the most frequent category is "Company Update" (163). The most recent is "Press Release" (Company Update), filed on 29 Oct 2026.
The disclosed corporate-action timeline lists 5 entries: dividend (5). The latest is a dividend (Final Dividend - Rs. - 0.5000) with ex-date 3 Jul 2026.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Pharmaceuticals. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Sun Pharmaceutical Industries Limited | Rs 1,761 | Rs 4,22,517 Cr | Rs 62,141 Cr | Rs 12,117 Cr | 34.94x | 15.53% |
| Divi's Laboratories Limited | Rs 9,664 | Rs 2,56,096 Cr | Rs 11,682 Cr | Rs 2,925 Cr | 87.69x | 18.44% |
| Torrent Pharmaceuticals Limited | Rs 4,580 | Rs 1,55,015 Cr | Rs 15,654 Cr | Rs 2,156 Cr | 73.16x | 27.30% |
| Laurus Labs Limited | Rs 2,244 | Rs 1,21,232 Cr | Rs 7,323 Cr | Rs 1,091 Cr | — | 22.38% |
| Zydus Lifesciences Limited | Rs 1,184.4 | Rs 1,18,203 Cr | Rs 29,052 Cr | Rs 4,593 Cr | 26.40x | 17.68% |
| Dr. Reddy's Laboratories Limited | Rs 1,345 | Rs 1,12,308 Cr | Rs 34,353 Cr | Rs 2,760 Cr | 40.02x | 7.84% |
| Cipla Limited | Rs 1,358 | Rs 1,09,706 Cr | Rs 28,855 Cr | Rs 2,854 Cr | 37.86x | 8.83% |
| Mankind Pharma Limited | Rs 2,469.3 | Rs 1,01,982 Cr | Rs 15,705 Cr | Rs 2,264 Cr | 45.45x | 14.78% |
| Aurobindo Pharma Limited | Rs 1,659.9 | Rs 95,511 Cr | Rs 35,625 Cr | Rs 3,711 Cr | 25.94x | 10.53% |
| Lupin Limited | Rs 1,989.9 | Rs 90,988 Cr | Rs 30,442 Cr | Rs 5,551 Cr | 16.44x | 27.89% |
| Glenmark Pharmaceuticals Limited | Rs 2,339 | Rs 66,007 Cr | Rs 18,236 Cr | Rs 1,798 Cr | 36.71x | 15.46% |
| Alkem Laboratories Limited | Rs 5,079 | Rs 60,719 Cr | Rs 15,681 Cr | Rs 2,204 Cr | 28.15x | 16.72% |
| Biocon LimitedThis company | Rs 351.9 | Rs 57,346 Cr | Rs 17,638 Cr | Rs 416 Cr | — | 1.78% |
| Abbott India Limited | Rs 26,145 | Rs 55,558 Cr | Rs 7,295 Cr | Rs 1,615 Cr | 34.41x | 35.85% |
| Gland Pharma Limited | Rs 3,074.5 | Rs 50,717 Cr | Rs 7,045 Cr | Rs 1,129 Cr | 44.88x | 11.57% |
| Median | Rs 2,244 | Rs 1,09,706 Cr | Rs 15,705 Cr | Rs 2,760 Cr | 36.40x | 16.72% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to Biocon
Same official industry (Pharmaceuticals)
- Sun Pharmaceutical Industries LimitedSUNPHARMA · Market cap Rs 4,22,517 Cr
- Divi's Laboratories LimitedDIVISLAB · Market cap Rs 2,56,096 Cr
- Torrent Pharmaceuticals LimitedTORNTPHARM · Market cap Rs 1,55,015 Cr
- Laurus Labs LimitedLAURUSLABS · Market cap Rs 1,21,232 Cr
- Zydus Lifesciences LimitedZYDUSLIFE · Market cap Rs 1,18,203 Cr
- Dr. Reddy's Laboratories LimitedDRREDDY · Market cap Rs 1,12,308 Cr
- Cipla LimitedCIPLA · Market cap Rs 1,09,706 Cr
- Mankind Pharma LimitedMANKIND · Market cap Rs 1,01,982 Cr
Other Healthcare companies of a similar market capitalisation
- Glenmark Pharmaceuticals LimitedGLENMARK · Market cap Rs 66,007 Cr
- Alkem Laboratories LimitedALKEM · Market cap Rs 60,719 Cr
- Fortis Healthcare LimitedFORTIS · Market cap Rs 56,992 Cr
- Abbott India LimitedABBOTINDIA · Market cap Rs 55,558 Cr
- Gland Pharma LimitedGLAND · Market cap Rs 50,717 Cr
- IPCA Laboratories LimitedIPCALAB · Market cap Rs 48,868 Cr
- Anthem Biosciences LimitedANTHEM · Market cap Rs 46,769 Cr
- Ajanta Pharma LimitedAJANTPHARM · Market cap Rs 43,367 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.